In the survival analysis with disease-free recurrence as the follow-up endpoint, TACR2 high-expressing prostate cancer patients had better survival outcomes than low-expressing patients (Fig. 1C, P < 0.001). The gene discussed is TACR2; the disease is Familial prostate cancer.